GO:0010972 negative regulation of G2/M transition of mitotic cell cycle: Cell Cycle Checkpoint Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010972 describes signaling pathways that decrease or inhibit cyclin-dependent protein kinase activity to block the switch from G2 phase to mitosis.
• The WEE1 kinase is a central negative regulator that phosphorylates CDK1 at inhibitory residues to prevent premature mitotic entry.
• Pin1 acts as a negative regulator of the G2/M transition by interacting with the Aurora-A-Bora complex.
• FOXC2 regulates the G2/M transition in stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.
• Dysregulation of G2/M negative regulators contributes to cancer, aging, and developmental disorders.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of these regulatory pathways.
Description
The G2/M transition is a critical checkpoint where cells verify that DNA replication is complete and damage is repaired before committing to mitosis. Negative regulation of this transition, annotated as GO:0010972, encompasses signaling pathways that inhibit cyclin-dependent protein kinase activity to delay or block mitotic entry. This regulatory mechanism is essential for maintaining genomic integrity and coordinating cell division with developmental and environmental cues. Research over three decades has identified key molecular players, including the WEE1 kinase, which phosphorylates CDK1 at inhibitory residues to keep the cell cycle arrested until conditions are favorable. The Pin1 prolyl isomerase also acts as a negative regulator by interacting with the Aurora-A-Bora complex, influencing mitotic timing. In cancer, FOXC2 has been shown to regulate the G2/M transition in stem cell-rich breast cancer cells, linking this pathway to tumor aggressiveness and therapeutic sensitivity. Understanding GO:0010972 is therefore central to cell cycle biology, cancer research, and the development of targeted therapies that exploit checkpoint vulnerabilities. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of the genes, mechanisms, and experimental models used to study negative regulation of the G2/M transition.
negative regulation of G2/M transition of mitotic cell cycle At A Glance
| GO ID | GO:0010972 |
|---|---|
| GO term | negative regulation of G2/M transition of mitotic cell cycle |
| Ontology | biological_process |
| Synonym | negative regulation of mitotic entry |
| Major function | Inhibits cyclin-dependent protein kinase activity to block the G2-to-M phase switch |
| Key kinases | WEE1, MYT1, and other inhibitory kinases that phosphorylate CDK1 |
| Key phosphatases | CDC25 family phosphatases that antagonize inhibitory phosphorylation |
| Associated processes | DNA damage checkpoint, cell cycle arrest, mitotic timing |
| Disease relevance | Cancer, aging, developmental disorders |
What Is GO:0010972?
GO:0010972, negative regulation of G2/M transition of mitotic cell cycle, is defined as any signaling pathway that decreases or inhibits the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the mitotic cell cycle. In simpler terms, it is the set of molecular brakes that prevent a cell from entering mitosis too early or with damaged DNA.
Why Is negative regulation of G2/M transition of mitotic cell cycle Important in Cell Biology?
Negative regulation of the G2/M transition is a fundamental safeguard that ensures genomic stability by preventing cells from entering mitosis with unrepaired DNA damage or incomplete replication. Its dysregulation is a hallmark of cancer, where loss of checkpoint control leads to uncontrolled proliferation and chromosomal instability. Moreover, this pathway is implicated in aging and developmental disorders, making it a prime target for therapeutic intervention and a critical area of cell cycle research.
• Prevents premature mitotic entry, preserving genomic integrity.
• Central to the DNA damage checkpoint and cell cycle arrest.
• WEE1 kinase is a key therapeutic target in cancer.
• Pin1-mediated regulation of Aurora-A-Bora influences mitotic timing.
• FOXC2 links G2/M regulation to breast cancer stem cell behavior.
• Dysregulation contributes to tumorigenesis and chemoresistance.
• Involved in aging pathways, as modeled in short-lived vertebrates.
• Provides targets for CRISPR-based functional genomics.
• Essential for understanding cell cycle control across eukaryotes.
• Enables development of combination therapies with PLK1 inhibitors.
What Happens During negative regulation of G2/M transition of mitotic cell cycle?
Inhibitory Phosphorylation of CDK1
In simple terms: A kinase adds a phosphate group to CDK1 to keep it inactive.
The core event in negative regulation of the G2/M transition is the phosphorylation of CDK1 at inhibitory residues (Thr14 and Tyr15) by WEE1 and MYT1 kinases. This modification prevents CDK1 from activating its downstream targets, thereby blocking entry into mitosis. WEE1 activity itself is cell cycle-regulated, peaking during G2 to ensure proper timing. Spatiotemporal regulation of WEE1 is critical for the G2/M transition, as its localization and degradation are tightly controlled.
Antagonism by CDC25 Phosphatases
In simple terms: Phosphatases remove the inhibitory phosphate to allow mitosis.
The inhibitory phosphorylation of CDK1 is reversed by CDC25 family phosphatases, which are themselves regulated by checkpoint kinases. The balance between WEE1/MYT1 and CDC25 activity determines whether the cell proceeds to mitosis. Negative regulation of the G2/M transition therefore involves signaling pathways that tip this balance toward inhibitory phosphorylation, often in response to DNA damage or incomplete replication.
Pin1 and the Aurora-A-Bora Complex
In simple terms: Pin1 acts as a brake on a complex that promotes mitosis.
Pin1, a prolyl isomerase, negatively regulates the G2/M transition by interacting with the Aurora-A-Bora complex. This interaction modulates the activity of Aurora-A, a kinase required for mitotic entry. By inhibiting Aurora-A-Bora function, Pin1 delays mitotic commitment, providing an additional layer of control beyond CDK1 phosphorylation.
Checkpoint Signaling and Cell Cycle Arrest
In simple terms: Surveillance pathways activate the brakes when problems are detected.
DNA damage or replication stress activates checkpoint kinases such as ATM/ATR and CHK1/CHK2, which in turn inhibit CDC25 phosphatases and activate WEE1. This signaling cascade reinforces CDK1 inhibition, leading to G2 arrest. In Aspergillus nidulans, regulation of p34cdc2/cyclinB and NIMA kinases during the G2/M transition and checkpoint responses highlights the evolutionary conservation of these mechanisms.
FOXC2 and Cancer Stem Cell Regulation
In simple terms: A transcription factor controls the G2/M brake in breast cancer stem cells.
FOXC2 regulates the G2/M transition in stem cell-rich breast cancer cells, and its expression sensitizes these cells to PLK1 inhibition. This suggests that FOXC2 modulates the negative regulation of the G2/M transition, contributing to the unique cell cycle properties of cancer stem cells. Targeting this pathway may offer therapeutic opportunities in aggressive breast cancers.
Key Genes Involved in GO:0010972 negative regulation of G2/M transition of mitotic cell cycle
The following genes and proteins are central to the negative regulation of the G2/M transition, as supported by verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| WEE1 | Phosphorylates CDK1 at Thr14/Tyr15 to inhibit mitotic entry | Target for cancer therapy and cell cycle studies |
| MYT1 | Membrane-associated kinase that phosphorylates CDK1 to reinforce inhibition | Checkpoint control and neuronal development |
| CDK1 | Cyclin-dependent kinase that drives mitosis; inhibited by phosphorylation | Central regulator of G2/M transition |
| CCNB1 | Cyclin B1, regulatory subunit of CDK1; binding is required for activity | Mitotic entry and cancer proliferation |
| CDC25A | Phosphatase that removes inhibitory phosphates from CDK1 | Checkpoint recovery and oncogenesis |
| CDC25B | Phosphatase that activates CDK1 at centrosomes | Mitotic timing and cancer |
| CDC25C | Phosphatase that activates CDK1 in the nucleus | G2/M transition and DNA damage response |
| PIN1 | Prolyl isomerase that negatively regulates G2/M via Aurora-A-Bora | Mitotic regulation and cancer |
| AURKA | Aurora kinase A, promotes mitotic entry; inhibited by Pin1 | Mitotic spindle assembly and cancer |
| BORA | Activator of Aurora-A; interacts with Pin1 | Mitotic commitment |
| FOXC2 | Transcription factor regulating G2/M in breast cancer stem cells | Cancer stem cell biology and PLK1 sensitivity |
| PLK1 | Polo-like kinase 1, promotes mitotic entry; inhibited by FOXC2 modulation | Therapeutic target in breast cancer |
| TP53 | Tumor suppressor that induces G2 arrest via p21 and WEE1 | DNA damage response and aging |
| CHEK1 | Checkpoint kinase 1, phosphorylates CDC25 and activates WEE1 | DNA damage checkpoint |
| CHEK2 | Checkpoint kinase 2, stabilizes WEE1 and inhibits CDC25 | Genomic stability and cancer predisposition |
| ATM | DNA damage sensor that initiates G2/M checkpoint signaling | Ataxia-telangiectasia and cancer |
| ATR | Replication stress sensor that activates CHK1 | Replication checkpoint and cancer |
How Is negative regulation of G2/M transition of mitotic cell cycle Regulated?
Negative regulation of the G2/M transition is itself tightly regulated by upstream signaling pathways. The DNA damage checkpoint, mediated by ATM/ATR and CHK1/CHK2, activates WEE1 and inhibits CDC25 phosphatases to enforce G2 arrest. Additionally, the p53/p66Shc aging pathway has been modeled in the short-lived vertebrate Nothobranchius furzeri, linking G2/M regulation to aging. FOXC2 provides a transcriptional layer of control in cancer stem cells, influencing sensitivity to PLK1 inhibition. These regulatory inputs ensure that mitotic entry is coordinated with cellular stress, developmental cues, and metabolic status.
negative regulation of G2/M transition of mitotic cell cycle and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| WEE1 | Cancer, chemoresistance | Knockout and point mutation in cancer cell lines |
| FOXC2 | Breast cancer stem cell aggressiveness | Overexpression and knockout in breast cancer cells |
| TP53 | Li-Fraumeni syndrome, aging | Knock-in of p53 mutations in zebrafish or cell lines |
| ATM | Ataxia-telangiectasia | Knockout in iPSCs and neuronal differentiation |
| CHEK1 | Cancer, replication stress | Point mutation of kinase domain in cancer cells |
Cancer
Dysregulation of the G2/M checkpoint is a hallmark of cancer. Loss of WEE1 or overexpression of CDC25 phosphatases can lead to premature mitotic entry and genomic instability. FOXC2-mediated regulation of the G2/M transition in breast cancer stem cells contributes to tumor aggressiveness and resistance to PLK1 inhibitors. Targeting WEE1 has emerged as a therapeutic strategy to sensitize cancer cells to DNA-damaging agents.
Aging and Neurodegeneration
The p53/p66Shc aging pathway, modeled in Nothobranchius furzeri, intersects with G2/M regulation, suggesting that negative regulation of the G2/M transition plays a role in aging and age-related diseases. In neurons, cell cycle re-entry is associated with neurodegeneration, and proper G2/M control may be protective.
Developmental Disorders
Proper control of the G2/M transition is essential for normal development. Mutations in checkpoint kinases such as ATM and ATR cause developmental and neurological disorders, partly due to defective cell cycle regulation. The plant cell cycle literature also underscores the evolutionary importance of G2/M control in growth and development.
From negative regulation of G2/M transition of mitotic cell cycle-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does WEE1 inhibition abrogate G2 arrest? | WEE1 knockout cell line |
| How does CDK1 phosphorylation affect mitotic timing? | CDK1 point mutation (T14A/Y15F) knock-in |
| What is the role of FOXC2 in breast cancer stem cells? | FOXC2 overexpression and knockout in mammospheres |
| Does Pin1 regulate Aurora-A-Bora interaction? | PIN1 knockout with tagged AURKA knock-in |
| How does p53/p66Shc pathway affect G2/M in aging? | Nothobranchius furzeri knockout models |
| Can CRISPR screening identify novel G2/M regulators? | Genome-wide CRISPR knockout library in HeLa cells |
How to Study the negative regulation of G2/M transition of mitotic cell cycle Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | DNA content and cell cycle distribution | Assessing G2/M arrest after gene knockout |
| Western blot | Protein expression and phosphorylation status | Quantifying CDK1 inhibitory phosphorylation |
| Live-cell imaging | Real-time mitotic entry dynamics | Visualizing cyclin B1 degradation and nuclear envelope breakdown |
| CRISPR knockout screening | Gene essentiality and pathway discovery | Identifying novel G2/M regulators |
| RNA-seq | Transcriptional changes | Profiling gene expression after WEE1 inhibition |
| Proteomics | Protein interactions and modifications | Mapping the WEE1 interactome |
| Immunofluorescence | Subcellular localization | Determining WEE1 and CDK1 localization during G2/M |
Cell Cycle Analysis by Flow Cytometry
Flow cytometry with DNA dyes (e.g., propidium iodide) measures DNA content to assess G2/M arrest. This method is widely used to evaluate the effects of WEE1 inhibitors or gene knockouts on cell cycle distribution.
Phospho-Specific Antibodies and Western Blotting
Western blotting with phospho-specific antibodies against CDK1 (Thr14/Tyr15) quantifies inhibitory phosphorylation. This is essential for determining whether a gene regulates the G2/M transition through CDK1 inhibition.
Live-Cell Imaging of Mitotic Entry
Fluorescent reporters for cyclin B1 or histone H2B allow real-time visualization of mitotic entry. This technique reveals dynamic regulation by WEE1, Pin1, and other factors.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify novel negative regulators of the G2/M transition. Combined with bioinformatics, this approach uncovers pathways and potential drug targets.
How CRISPR Can Be Used to Study GO:0010972 negative regulation of G2/M transition of mitotic cell cycle
Knockout
CRISPR knockout of WEE1 or other negative regulators results in premature mitotic entry and cell death, validating their essential role in the G2/M checkpoint. Knockout cell lines are powerful tools for studying checkpoint abrogation and drug sensitivity.
Point Mutation
Point mutations in CDK1 at Thr14 and Tyr15 (to alanine or phenylalanine) prevent inhibitory phosphorylation, leading to constitutive mitotic entry. Such knock-in models help dissect the precise contribution of phosphorylation sites to G2/M regulation.
Knock-in
Knock-in of tagged WEE1 or PIN1 allows for live-cell imaging and proteomic analysis of their dynamic localization and interactions during the G2/M transition. This approach provides spatiotemporal resolution of negative regulation.
Overexpression
Overexpression of FOXC2 or WEE1 can induce G2 arrest and alter sensitivity to PLK1 inhibitors. Overexpression models are useful for studying gain-of-function effects and identifying downstream targets.
How EDITGENE Supports negative regulation of G2/M transition of mitotic cell cycle Research
Researchers studying negative regulation of G2/M transition of mitotic cell cycle-related genes often need to determine whether a candidate gene is causally involved in checkpoint control, and to dissect the precise phosphorylation events that govern mitotic entry. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of G2/M transition of mitotic cell cycle research.
Frequently Asked Questions About negative regulation of G2/M transition of mitotic cell cycle
What is GO:0010972?
GO:0010972 is the Gene Ontology term for negative regulation of G2/M transition of mitotic cell cycle, describing signaling pathways that inhibit cyclin-dependent protein kinase activity to block entry into mitosis.
What genes are involved in negative regulation of G2/M transition?
Key genes include WEE1, MYT1, CDK1, CCNB1, CDC25A/B/C, PIN1, AURKA, BORA, FOXC2, PLK1, TP53, CHEK1, CHEK2, ATM, and ATR.
How does WEE1 regulate the G2/M transition?
WEE1 phosphorylates CDK1 at Thr14 and Tyr15, inhibiting its activity and preventing mitotic entry until the cell is ready.
What is the role of Pin1 in the G2/M transition?
Pin1 acts as a negative regulator by interacting with the Aurora-A-Bora complex, thereby delaying mitotic commitment.
How is FOXC2 involved in breast cancer G2/M regulation?
FOXC2 regulates the G2/M transition in stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.
What diseases are associated with dysregulation of the G2/M checkpoint?
Cancer, aging-related disorders, and developmental syndromes such as ataxia-telangiectasia are linked to G2/M checkpoint dysfunction.
How can CRISPR be used to study negative regulation of G2/M transition?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal dissection of genes like WEE1, CDK1, and PIN1 in cell cycle control.
What methods are used to measure G2/M transition regulation?
Flow cytometry, Western blotting for phospho-CDK1, live-cell imaging, and CRISPR screens are commonly used.
Is WEE1 a therapeutic target in cancer?
Yes, WEE1 inhibitors are being developed to abrogate the G2/M checkpoint and sensitize cancer cells to DNA-damaging agents.
What model organisms are used to study G2/M regulation?
Aspergillus nidulans, Nothobranchius furzeri, and mammalian cell lines are used to study conserved mechanisms.
Conclusion
Negative regulation of the G2/M transition (GO:0010972) is a cornerstone of cell cycle control, ensuring genomic integrity by preventing premature mitosis. The interplay between WEE1, CDC25 phosphatases, Pin1, and FOXC2 highlights the complexity of this regulatory network and its implications in cancer, aging, and development. CRISPR-based models are indispensable for dissecting these pathways and identifying new therapeutic targets. EDITGENE's comprehensive services empower researchers to explore GO:0010972 with precision and speed.
References
- 1. McGowan CH et al.. 1995. Cell cycle regulation of human WEE1.. EMBO J 14(10):2166-75 PMID: 7774574
- 2. Pietilä M et al.. 2016. FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.. Sci Rep 6:23070 PMID: 27064522
- 3. Francis D. 2007. The plant cell cycle--15 years on.. New Phytol 174(2):261-278 PMID: 17388890
- 4. Lee YC et al.. 2013. Pin1 acts as a negative regulator of the G2/M transition by interacting with the Aurora-A-Bora complex.. J Cell Sci 126(Pt 21):4862-72 PMID: 23970419
- 5. Nigg EA et al.. 1992. Regulation of p34cdc2 protein kinase activity by phosphorylation and cyclin binding.. Ciba Found Symp 170:72-84; discussion 84-96 PMID: 1483352
- 6. Masuda H et al.. 2011. Spatiotemporal regulations of Wee1 at the G2/M transition.. Mol Biol Cell 22(5):555-69 PMID: 21233285
- 7. Ye XS et al.. 1997. Regulation of p34cdc2/cyclinB H1 and NIMA kinases during the G2/M transition and checkpoint responses in Aspergillus nidulans.. Prog Cell Cycle Res 3:221-32 PMID: 9552417
- 8. Priami C et al.. 2015. Modelling the p53/p66Shc Aging Pathway in the Shortest Living Vertebrate Nothobranchius Furzeri.. Aging Dis 6(2):95-108 PMID: 25821638
